Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Qatar’s state oil giant QatarEnergy said on Wednesday (March 18, 2026) that “extensive damage” has been caused ‌after the Ras Laffan Industrial City was subjected to missile attacks, shortly ⁠after ...

It's draft month, and there's one Clemson Tiger who could be rising up every team's draft board until everybody's name is called. Now, that agenda might be changing. In a metric titled “relative ...

A Revolution Medicines drug helped pancreatic cancer patients live nearly six months longer compared to those treated with standard of care chemotherapy, meeting the goals of a pivotal study in this ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

Revolution Medicines said its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...

RPSC RAS mains 2025 result: The Rajasthan Public Service Commission (RPSC) has officially released the RPSC RAS mains result 2025. Candidates who appeared for the mains examination can now access ...